β-Blockers for Primary Prevention in Hypertension: Era Bygone?

Progress in Cardiovascular Diseases

Volumn 49, Issue 2, 2006, Pages 76-87

  Panjrath, Gurusher S ^a   Messerli, Franz H ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARTEOLOL; CARVEDILOL; CELIPROLOL; DIGOXIN; DILTIAZEM; ENALAPRIL; ESMOLOL; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; NADOLOL; NEBIVOLOL; OXPRENOLOL; PENBUTOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; UNINDEXED DRUG; VERAPAMIL;

ALOPECIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRONCHOSPASM; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG USE; DYSPEPSIA; DYSPNEA; EDEMA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXFOLIATIVE DERMATITIS; EYE IRRITATION; FATIGUE; FLATULENCE; HALLUCINATION; HEART ARREST; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOGLYCEMIA; IMPOTENCE; INSOMNIA; JAUNDICE; LACRIMATION; LIBIDO DISORDER; LIVER NECROSIS; METABOLIC DISORDER; MYALGIA; NAUSEA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PHARYNGITIS; PRURITUS; QT PROLONGATION; SIDE EFFECT; SINUS BRADYCARDIA; SYNCOPE; TORSADE DES POINTES; URINE RETENTION; VASOCONSTRICTION; VOMITING; WEIGHT GAIN; WHEEZING; XEROSIS;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PRIMARY PREVENTION;

EID: 33749872224     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.07.002     Document Type: Article

References (62)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289 (2003) 2560-2572
2. Cruickshank J.M., and PB. Beta-blockers in clinical practice. 2nd ed (1994), Edinburgh, Churchill-Livingstone 1-1204
3. McDevitt D.G. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur. Heart. J. 8 Suppl M (1987) 9-14
4. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on antihypertensive agents. JAMA 248 (1982) 2004-2011
5. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br. Med. J. (Clin Res Ed). 291 (1985) 97-104
6. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J. Hypertens. 3 (1985) 379-392
7. Coope J., and Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. (Clin Res Ed). 293 (1986) 1145-1151
8. Berglund G., Andersson O., and Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med. Scand. 220 (1986) 419-424
9. Wilhelmsen L., Berglund G., Elmfeldt D., et al. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial. J. Hypertens. 5 (1987) 561-572
10. Dahlof B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338 (1991) 1281-1285
11. Yurenev A.P., Dyakonova H.G., Novikov I.D., et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am. J. Hypertens. 5 6 Pt 2 (1992) 182S-189S
12. Medical Research Council trial of treatment of hypertension in older adults: Principal results. MRC working party. BMJ 304 (1992) 405-412
13. Eriksson S.E., and Olsson J.E. Survival and recurrent strokes in patients with different subtypes of stroke: A fourteen-year follow-up study. Cerebrovasc. Dis. 12 (2001) 171-180
14. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Bmj. 310 (1995) 83-88
15. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
16. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999) 1751-1756
17. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 356 (2000) 359-365
18. Zanchetti A., Bond M.G., Hennig M., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 (2002) 2422-2427
19. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288 (2002) 2421-2431
20. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
21. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke 24 (1993) 543-548
22. Black H.R., Elliott W.J., Grandits G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289 (2003) 2073-2082
23. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290 (2003) 2805-2816
24. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366 (2005) 895-906
25. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: Is it a wise choice?. Lancet 364 (2004) 1684-1689
26. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
27. Beevers D.G. The end of beta blockers for uncomplicated hypertension?. Lancet. 366 (2005) 1510-1512
28. Messerli F.H., Grossman E., and Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279 (1998) 1903-1907
29. Khan N., and McAlister F.A. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ 174 (2006) 1737-1742
30. Messerli F.H., Sundgaard-Riise K., Ventura H.O., et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 2 (1983) 983-986
31. Weber K., Bohmeke T., van der Does R., et al. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc. Drugs Ther. 10 (1996) 113-117
32. Grossman E., and Messerli F.H. Why beta-blockers are not cardioprotective in elderly patients with hypertension. Curr. Cardiol. Rep. 4 (2002) 468-473
33. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115 (2003) 41-46
34. Schulman S.P., Weiss J.L., Becker L.C., et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N. Engl. J. Med. 322 (1990) 1350-1356
35. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA 246 (1981) 2073-2074
36. Pedersen T.R. The Norwegian multicenter study of timolol after myocardial infarction. Circulation 67 6 Pt 2 (1983) I49-I53
37. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
38. Houghton T., Freemantle N., and Cleland J.G.F. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur. J. Heart Fail. 2 (2000) 333-340
39. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250 (1983) 2814-2819
40. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 339 (1998) 489-497
41. Mickley H., Eiskjaer H., and Botker H.E. Is an additional post-myocardial infarction beta-blocker trial required in the era of early revascularization?. Eur. Heart J. 25 (2004) 96-97
42. Chen Z.M., Pan H.C., Chen Y.P., et al. Commit (CLOPIDOGREL and METOPROLOL in Myocardial Infarction Trial) Collaboration Group. Lancet 366 (2005) 1622-1632
43. Bengtsson C., Blohme G., Lapidus L., et al. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: A 12-year prospective population study of women in Gothenburg, Sweden. J. Intern. Med. 231 (1992) 583-588
44. Pollare T., Lithell H., Selinus I., et al. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298 (1989) 1152-1157
45. Ehmer B., van der Does R., and Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics. Drugs 36 Suppl 6 (1988) 136-140
46. Poirier L., Cleroux J., Nadeau A., et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. 19 (2001) 1429-1435
47. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet. 362 (2003) 7-13
48. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292 (2004) 2227-2236
49. Vernon C., and Sakula A. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol. Br. J. Clin. Pract. 33 (1979) 112-121
50. Messerli F.H., Beevers D.G., Franklin S.S., et al. beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am. J. Hypertens. 16 (2003) 870-873
51. Heitmann M., Davidsen U., Stokholm K.H., et al. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure. Scand. J. Clin. Lab. Invest. 62 (2002) 97-104
52. Houston M.C., and Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am. Heart J. 116 2 Pt 1 (1988) 515-523
53. Psaty B.M., Koepsell T.D., Wagner E.H., et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 263 (1990) 1653-1657
54. Cruickshank J.M. Beta-blockers continue to surprise us. Eur. Heart J. 21 (2000) 354-364
55. Grimm Jr. R.H. Antihypertensive therapy: taking lipids into consideration. Am. Heart J. 122 3 Pt 2 (1991) 910-918
56. Chen J., Radford M.J., Wang Y., et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 7 (2001) 1950-1956
57. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 2 (1981) 539-543
58. Messerli F.H., and Grossman E. Beta-blocker therapy and depression. JAMA 16 288 (2002) 1845-1846 [author reply 1846]
59. Salem S.A., and McDevitt D.G. Central effects of beta-adrenoceptor antagonists. Clin. Pharmacol. Ther. 33 (1983) 52-57
60. Messerli F.H., and Grossman E. Beta-blockers in hypertension: Is carvedilol different?. Am. J. Cardiol. 93 (2004) 7B-12B
61. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
62. Kelly R., Daley J., Avolio A., et al. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 14 (1989) 14-21